Patents by Inventor Susan McArdle

Susan McArdle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5328835
    Abstract: A method for expressing proteins which are immunologically reactive with antibodies to lymphadenopathy-associated virus (LAV), now known as Human Immunodeficiency Virus (HIV), is disclosed. The proteins are produced by bacterial host cells transformed with a recombinant plasmid which includes appropriate procaryotic transcriptional and translational signals for expression, followed in reading phase by a DNA sequence comprising a portion of the env region of the LAV genome. This portion codes for a protein which is immunologically reactive with antibodies to LAV, or antibodies to viruses defined to be the same as or equivalent to LAV. The proteins produced by the method disclosed may be used to screen for the presence of antibodies to LAV in a biological fluid, to determine the presence of LAV antigen in a biological fluid, or within a method for producing antibodies to LAV through the immunization of an animal with the protein.
    Type: Grant
    Filed: August 24, 1992
    Date of Patent: July 12, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Suan M. Watanabe, Wesley L. Cosand, Susan McArdle, Bruce M. Travis
  • Patent number: 5175098
    Abstract: Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising a portion of the gag region of LAV. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagonstic assays which detect the presence of LAV antigens or antibodies immunologically reactive with LAV. Further, the proteins produced by the method disclosed may be used as a vaccine against infection by the caustive virus for acquired immune deficiency syndrome.
    Type: Grant
    Filed: July 28, 1989
    Date of Patent: December 29, 1992
    Assignee: Genetic Systems Corporation
    Inventors: Susan M. Watanabe, Wesley L. Cosand, Susan McArdle, Pamela J. Ward
  • Patent number: 5175097
    Abstract: Immunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising pGAG-1. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagnostic assays which detect the presence of LAV/HTLV-III antigens or antibodies immunologically reactive with LAV/HTLV-III. Further, the proteins produced by the method disclosed may be used as a vaccine against infection by the causative virus for acquired immune deficiency syndrome.
    Type: Grant
    Filed: September 10, 1990
    Date of Patent: December 29, 1992
    Assignee: Genetic Systems Corporation
    Inventors: Susan M. Watanabe, Wesley L. Cosand, Susan McArdle, Pamela J. Ward
  • Patent number: 4784941
    Abstract: A method of expressing peptides which are immunologically reactive with antibodies to LAV is disclosed. The peptides are produced by bacterial host cells transformed with a recombinant plasmid which includes appropriate procaryotic transcriptional and translational signals for expression, followed by a DNA sequence coding for a peptide comprising the amino acid sequence as shown in FIG. 5 starting with isoleucine, number 1, and ending with threonine, number 173. The peptides of the present invention are immunologically reactive with antibodies to LAV, or antibodies to viruses defined to be the same as or equivalent to LAV. The peptides produced by the method disclosed may be used to screen for the presence of antibodies to LAV in a biological fluid, to determine the presence of LAV antigen in a biological fluid, or within a method for producing antibodies to LAV through the immunization of an animal with the peptide.
    Type: Grant
    Filed: October 2, 1985
    Date of Patent: November 15, 1988
    Assignee: Genetic Systems Corporation
    Inventors: Susan M. Watanabe, Wesley L. Cosand, Susan McArdle, Bruce M. Travis